Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
{
"resourceType" : "Composition",
"id" : "370504",
"meta" : {
"versionId" : "24",
"lastUpdated" : "2025-08-18T13:22:42.074Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 370504</b></p><a name=\"370504\"> </a><a name=\"hc370504\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 24; Last updated: 2025-08-18 13:22:42+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-outcome-measure-report.html\">OutcomeMeasureReport</a></p></div><p><b>ArtifactPublicationStatus</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}\">Active</span></p><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/370504\">https://fevir.net/resources/Composition/370504</a></p><p><b>identifier</b>: FEvIR Object Identifier/370504, FEvIR Linking Identifier/NCT03640312-outcome-measure-report</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 OutcomeMeasureReport}\">Outcome Measure Report</span></p><p><b>date</b>: 2025-08-18 13:22:42+0000</p><p><b>author</b>: [No author listed.]</p><p><b>title</b>: Outcome Measures Report for NCT03640312</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>Cite As</td><td><div><p>Outcome Measures Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370504. Revised 2025-08-18. Available at: https://fevir.net/resources/Composition/370504. Computable resource at: https://fevir.net/FLI/DocumentForComposition370504.</p>\n</div></td></tr></table></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code" : "active",
"display" : "Active"
}
]
}
}
],
"url" : "https://fevir.net/resources/Composition/370504",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net/FOI",
"value" : "370504",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-outcome-measure-report",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "OutcomeMeasureReport",
"display" : "OutcomeMeasureReport"
}
],
"text" : "Outcome Measure Report"
},
"date" : "2025-08-18T13:22:42.074Z",
"author" : [
{
"display" : "[No author listed.]"
}
],
"title" : "Outcome Measures Report for NCT03640312",
"custodian" : {
🔗 "reference" : "Organization/118079",
"type" : "Organization",
"display" : "Computable Publishing LLC"
},
"relatesTo" : [
{
"type" : "cite-as",
"targetMarkdown" : "Outcome Measures Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370504. Revised 2025-08-18. Available at: https://fevir.net/resources/Composition/370504. Computable resource at: https://fevir.net/FLI/DocumentForComposition370504."
}
],
"section" : [
{
"title" : "Change in Mean Systolic Blood Pressure at 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367882",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-primaryOutcome-0",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367882",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-primaryOutcome-0",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367903",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-primaryOutcomeMeasure-0--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367904",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-primaryOutcomeMeasure-0--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367941",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-primaryOutcomeMeasure-0-OutcomeAnalysis-0-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Mean Systolic Blood Pressure at 6 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367883",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-0",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367883",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-0",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367905",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-0--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367906",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-0--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367942",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-0-OutcomeAnalysis-1-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Change in Mean Diastolic Blood Pressure at 6 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367884",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-1",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367884",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-1",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367907",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-1--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367908",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-1--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367943",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-1-OutcomeAnalysis-2-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Mean Diastolic Blood Pressure at 6 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367885",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-2",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367885",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-2",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367909",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-2--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367910",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-2--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367944",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-2-OutcomeAnalysis-3-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367886",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-3",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 and 12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/370506",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-3-6-weeks-",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367911",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-3-6-weeks-OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367912",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-3-6-weeks-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312"
}
]
},
{
"title" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/370507",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-3-12-weeks-",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367913",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-3-12-weeks-OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367914",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-3-12-weeks-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312"
}
]
}
]
},
{
"title" : "Outcome Analysis List for Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
],
"text" : "OutcomeAnalysisList"
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367886",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-3",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367945",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-3-OutcomeAnalysis-4-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
},
{
"title" : "Number of Patients Requiring Step up Treatment at 6 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367887",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-4",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367887",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-4",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367915",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-4--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367916",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-4--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367946",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-4-OutcomeAnalysis-5-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367888",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-5",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367888",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-5",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367917",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-5--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367918",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-5--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367947",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-5-OutcomeAnalysis-6-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Medication Adherence at 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367889",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-6",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Medication Adherence at 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Medication Adherence at 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367889",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-6",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Medication Adherence at 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367919",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-6--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367920",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-6--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Medication Adherence at 12 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367948",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-6-OutcomeAnalysis-7-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Health-related Quality of Life at 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367890",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-7",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Health-related Quality of Life at 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Data are available on only 28 participants in the intervention group for the mental health T score.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/370508",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367921",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367922",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312"
}
]
},
{
"title" : "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/370509",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367923",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367924",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312"
}
]
}
]
},
{
"title" : "Outcome Analysis List for Health-related Quality of Life at 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
],
"text" : "OutcomeAnalysisList"
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367890",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-7",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Health-related Quality of Life at 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367949",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-7-OutcomeAnalysis-8-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367950",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-7-OutcomeAnalysis-9-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
},
{
"title" : "Change in Mean Systolic Blood Pressure at 6 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367891",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-8",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367891",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcome-8",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367925",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-8--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367926",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-8--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367951",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-secondaryOutcomeMeasure-8-OutcomeAnalysis-10-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367896",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-0",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367896",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-0",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367927",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-0--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367928",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-0--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367952",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-0-OutcomeAnalysis-11-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Percentage of Participants With Potentially Related Adverse Events at 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367897",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-1",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367897",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-1",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367929",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-1--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367930",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-1--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367953",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-1-OutcomeAnalysis-12-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Rate of Adverse Events of Special Interest at 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367898",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-2",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367898",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-2",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367931",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-2--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367932",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-2--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367954",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-2-OutcomeAnalysis-13-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Mean Change in Serum Potassium at 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367899",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-3",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Potassium at 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Mean Change in Serum Potassium at 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367899",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-3",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Potassium at 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367933",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-3--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367934",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-3--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367955",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-3-OutcomeAnalysis-14-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Mean Change in Serum Sodium at 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367900",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-4",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Sodium at 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Mean Change in Serum Sodium at 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367900",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-4",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Sodium at 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367935",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-4--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367936",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-4--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367956",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-4-OutcomeAnalysis-15-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Mean Change in Blood Urea Nitrogen at 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367901",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-5",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367901",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-5",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367937",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-5--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367938",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-5--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367957",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-5-OutcomeAnalysis-16-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title" : "Mean Change in Serum Creatinine at 12 weeks",
"focus" : {
🔗 "reference" : "EvidenceVariable/367902",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-6",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "QUARTET LDQT",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title" : "Candesartan",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry" : [
{
"display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/367902",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcome-6",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)"
},
"entry" : [
{
🔗 "reference" : "Evidence/367939",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-6--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
🔗 "reference" : "Evidence/367940",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-6--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312"
},
{
🔗 "reference" : "Evidence/367958",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-otherOutcomeMeasure-6-OutcomeAnalysis-17-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot2 based on FHIR 6.0.0-ballot3. Generated 2025-09-04
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change